← Back to Search

GLP-1 Receptor Agonist

Exenatide for Parkinson's Disease

Phase 1
Waitlist Available
Led By David Vaillancourt, PhD
Research Sponsored by University of Florida
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and one-year
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

This trial is testing Exenatide, a diabetes medication, to see if it can help people with Parkinson's Disease by improving their symptoms and slowing down the disease. The study focuses on people with Parkinson's because they might benefit from these potential effects. Exenatide may help the brain function better and protect brain cells, leading to better movement and slower disease progression. Exenatide has shown potential benefits in improving motor and non-motor symptoms in Parkinson's disease in previous studies.

Eligible Conditions
  • Parkinson's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and one-year
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and one-year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in blood oxygen level-dependent(BOLD) signal in M1.
Change in blood oxygen level-dependent(BOLD) signal in the posterior putamen.
Change in blood oxygen level-dependent(BOLD) signal in the supplementary motor area(SMA).
+1 more

Side effects data

From 2017 Phase 4 trial • 8 Patients • NCT02058940
38%
Death
100%
80%
60%
40%
20%
0%
Study treatment Arm
Exenatide

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: ExenatideExperimental Treatment1 Intervention
This group will receive a weekly Exenatide 2mg injection for one year.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Exenatide
FDA approved

Find a Location

Who is running the clinical trial?

University of FloridaLead Sponsor
1,397 Previous Clinical Trials
767,022 Total Patients Enrolled
National Institute of Neurological Disorders and Stroke (NINDS)NIH
1,377 Previous Clinical Trials
651,832 Total Patients Enrolled
David Vaillancourt, PhDPrincipal InvestigatorUniversity of Florida
3 Previous Clinical Trials
51 Total Patients Enrolled
~1 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top